Business
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
The Company holds a U.S. patent for the same treatment FREMONT, CA - (NewMediaWire) - February 12, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a
About this update from Abvc Biopharma, Inc.
[{"type":"text","content":"The Company holds a U.S. patent for the same treatment\nFREMONT, CA - (NewMediaWire) - February 12, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) (\"Company\"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received an Australian patent, valid until 2040, Application No. 2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD). The Company was previously awarded a U.S. patent, US 11,554,154 B2, on April 25, 2023, for the same treatment.\n\n\"These patents grant ABVC the right to exclude others from using, offering, or selling PDC-1421 throughout the United States and Australia until 2040,\" said Dr. Uttam Patil, ABVC Chief Executive Officer. \"As our patent map steps into global coverage, we eagerly await the results of patent applications in the European Union, China, Japan, and more.\"\nThe patent application was submitted to the Australian Patent and Trademark Office under \"Polygala Extract for the Treatment of Major Depressive Disorder.\" The invention relates to oral administration of the formulation containing a Radix Polygala (Polygala tenuifolia Willd) extract, PDC-1421, as a capsule for treating Major Depressive Disorder. Based on the Company's current internal studies, administering the composition should be done over at least 25 days, with the daily dose varying once, twice, or three times per day; each dose ranges between 380-760 mg of the botanical extraction.\nABV-1504, the Company's asset indicated for use in MDD containing PDC-1421, is a botanical-based Norepinephrine Transporter (NET) inhibitor that has completed Phase II clinical studies, with plans to initiate an End of Phase II (EOP II) meeting with the FDA. The CNS drugs with the indications of MDD and ADHD (Attention Deficit Hyperactivity Disorder) have been valued globally at $667M by a third-party valuation company and licensed to AiBtl BioPharma Inc. (\"AiBtl\") on November 12, 2023 by entering into a definitive global licensing agreement. According to the terms of the agreement, AiBtl delivered 46M shares to the Company as the first milestone payment. The Company expects AiBtl to achieve the further milestones under the agreeme...